Literature DB >> 23734777

Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy.

M Blondon, K L Wiggins, L B Harrington, B M Psaty, N L Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23734777      PMCID： PMC4363936          DOI： 10.1111/jth.12309

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  7 in total

1.  Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER study.

Authors:  Marianne Canonico; Valérie Olié; Laure Carcaillon; Pascale Tubert-Bitter; Pierre-Yves Scarabin
Journal:  Thromb Haemost       Date:  2008-01       Impact factor: 5.249

2.  Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation.

Authors:  Ellen B Gold; Alicia Colvin; Nancy Avis; Joyce Bromberger; Gail A Greendale; Lynda Powell; Barbara Sternfeld; Karen Matthews
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

3.  Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.

Authors:  J Bouligand; O Cabaret; M Canonico; C Verstuyft; L Dubert; L Becquemont; A Guiochon-Mantel; P Y Scarabin
Journal:  Clin Pharmacol Ther       Date:  2010-11-24       Impact factor: 6.875

4.  Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.

Authors:  Marianne Canonico; Elodie Bouaziz; Laure Carcaillon; Céline Verstuyft; Anne Guiochon-Mantel; Laurent Becquemont; Pierre-Yves Scarabin
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

5.  Estrogen plus progestin and risk of venous thrombosis.

Authors:  Mary Cushman; Lewis H Kuller; Ross Prentice; Rebecca J Rodabough; Bruce M Psaty; Randall S Stafford; Steven Sidney; Frits R Rosendaal
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

6.  Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.

Authors:  Nicholas L Smith; Susan R Heckbert; Rozenn N Lemaitre; Alex P Reiner; Thomas Lumley; Noel S Weiss; Eric B Larson; Frits R Rosendaal; Bruce M Psaty
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

7.  Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.

Authors:  S Sweetland; V Beral; A Balkwill; B Liu; V S Benson; M Canonico; J Green; G K Reeves
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.